Synairgen (SNG)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

160.30p
   
  • Change Today:
    -2.00p
  • 52 Week High: 224.66p
  • 52 Week Low: 77.00p
  • Currency: UK Pounds
  • Shares Issued: 201.34m
  • Volume: 646,472
  • Market Cap: £322.75m
  • RiskGrade: 510

Synairgen drug proves effective against Covid variants in lab tests

By Abigail Townsend

Date: Monday 24 May 2021

LONDON (ShareCast) - (Sharecast News) - A drug being developed by Synairgen to treat severe lung infections has shown promising laboratory results against emerging variants of Covid-19, the biotech announced on Monday.
The UK firm, a specialist in clinical-stage respiratory drug discovery and development, is developing an inhaled formulation of interferon beta, known as SNG001, as a broad-spectrum antiviral for severe lung infections. It is currently being used in Covid-19 trials in hospital and community settings.

Following the emergence of new variants, however, in-vitro experiments have been carried out to demonstrate the antiviral activity of SNG001 against the so-called Kent and South African variants of Covid-19.

Synairgen said that SNG001 "potently reduced virus to undetectable levels" in cells infected with the original Wuhan strain, the Kent variant and the South African variant.

Richard Marsden, chief executive, said: "As expected, these data confirm that SNG001 is a broad-spectrum antiviral product now also demonstrating applicability against SARS-CoV-2 variants.

"Alongside vaccines, our lines of defence against this pandemic and future outbreaks rely in part on access to effective antivirals with broad-spectrum activity against a range of viruses and variants."

Stephen Holgate, medical research council clinical professor of immunopharmacology at the University of Southampton, said: "These data are not surprising, and confirm the broad-spectrum antiviral activity of SNG001...which is important in the context of our ongoing phase III trial in hospitalised patients and future use of this drug against SARS-CoV-2 and other emerging viral threats."

Synairgen was founded by Holgate and fellow University of Southampton professors Donna Davies and Ratko Djukanovic before being spun out and listed on AIM in 2004.

As at 1100 BST, shares in Synairgen were 8% higher at 114.32p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Synairgen Market Data

Currency UK Pounds
Share Price 160.30p
Change Today -2.00p
% Change -1.23 %
52 Week High 224.66p
52 Week Low 77.00p
Volume 646,472
Shares Issued 201.34m
Market Cap £322.75m
RiskGrade 510

Synairgen Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
48.64% above the market average48.64% above the market average48.64% above the market average48.64% above the market average48.64% above the market average
92.00% above the sector average92.00% above the sector average92.00% above the sector average92.00% above the sector average92.00% above the sector average
Price Trend
0.84% below the market average0.84% below the market average0.84% below the market average0.84% below the market average0.84% below the market average
19.35% above the sector average19.35% above the sector average19.35% above the sector average19.35% above the sector average19.35% above the sector average
Income
5.46% above the market average5.46% above the market average5.46% above the market average5.46% above the market average5.46% above the market average
63.64% above the sector average63.64% above the sector average63.64% above the sector average63.64% above the sector average63.64% above the sector average
Growth Not Available

What The Brokers Say

Strong Buy 1
Buy 0
Neutral 0
Sell 0
Strong Sell 0
Total 1
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Synairgen Dividends

No dividends found

Trades for 23-Sep-2021

Time Volume / Share Price
16:35 937 @ 160.30p
16:35 4,949 @ 160.30p
16:29 307 @ 161.00p
16:29 245 @ 161.00p
16:29 25 @ 161.00p

Synairgen Key Personnel

CEO Richard J Marsden
Finance Director John C Ward

Top of Page